Dako Introduces Unique Package of RTU Antibodies for Cancer Diagnostics

Dako A/S's new set of ready-to-use antibodies, Flex RTU, is the largest and most clinically relevant antibody portfolio on the market. It has been developed for diagnosis of the most common types of cancer such as breast, colon, lung, prostate, melanoma, etc.

With the number of patients waiting for cancer diagnosis continually on the rise, Dako works to provide pathology laboratories with workflow solutions linking knowledge, reagents, instruments and software for fast and accurate answers.

The set of 61 new, ready-to-use antibodies, Flex RTU, has been designed to deliver unique staining performance through collaboration with leading international pathologists, improved laboratory efficiency by reducing hands-on time and improving system efficiency, increased productivity by speeding up the process from test to diagnosis, and increased patient safety due to fewer errors.

For further information please contact:

Maria Fredtoft Søchting,
Corporate Communications

Tel: +45 25 46 10 83

Email: contact@dako.com

Or visit: www.dako.com